The availability of 6.4 million prescription medicines have been hit each month so far this year because of shortages, including certain brands of insulin, blood pressure treatments and chemotherapy drugs, according to an analysis by the National Pharmacy Association (NPA)
Its examination of Medicine Supply Notifications (MSNs), issued by the Department of Health and Social Care (DHSC) when medicines are no longer in supply or there are supply constraints in place, revealed 14 MSNs might have impacted prescriptions each month.
The findings prompted the NPA to call on health secretary Yvette Cooper to urgently publish an “action plan to tackle the growing problem of medicine shortages and improve the UK’s resilience to medicine supply disruption”.
The NPA found MSNs have been issued for numerous commonly prescribed medicines, including different strengths of the blood pressure drug Ramipril and the painkiller co-codamol as well as forms of the hormone replacement therapy medication Estradot.
MSNs have also been issued for Nabilone, which manages the side-effects of chemotherapy, and Creon, which helps people with cystic fibrosis and pancreatic cancer digest food.
The NPA urged Labour to publish its response to its consultation, which closed in December last year, on proposals allowing pharmacists to supply a different strength or formulation of the same medicine when it is unavailable.
The All-Party Pharmacy Group made the same call to the Government last month. Independent Community Pharmacist has contacted the DHSC for a response.
“(Pharmacists) are prevented from making any changes to a prescription in the majority of cases, even to switch tablets to capsules or an ointment to a cream, by legislation that dates back to before the moon landings in 1969,” the NPA said.
'Spiralling' price of medicines forces pharmacists to dispense at a loss
The NPA also warned the “spiralling” price of medicines is continuing to force pharmacists to dispense at a loss and reiterated its call for the reimbursement system, often described by pharmacy leaders as “broken”, to be fixed.
“Volatility in medicine prices hit pharmacies who have to buy NHS medicines on the open market and can act as an early warning of supply issues as demand spikes or supply is constrained,” the NPA said.
It claimed the DHSC has “broken records” for the number of price concessions it has issued this year, with 245 concessions issued last month alone compared to 100 in October last year.
“The cost of Levothyroxine, a common thyroid treatment, has increased by more than 18 times between October 2025 and October 2026, rising from 18p to £3.29,” the NPA said.
“Similarly, the antibiotic Oxytetracycline is now 91 times higher than it was in January 2024, rising from 57p to £51.89.” The NPA chair Olivier Picard said the findings of its analysis were “shocking”.
“Despite Government claims that the situation with medicine supply may be improving, this simply does not match the reality that pharmacies and the patients they serve are seeing on the ground,” he said.
“Problems with medicine supply can not only cause significant anxiety and frustration for patients but also can pose a serious safety risk, particularly for time critical medicines such as insulin and some antiepileptic treatments.”
Picard urged Cooper to “grip this problem head on” and overturn “mad rules that stop pharmacists from making any changes to a prescription when a medicine is out of stock, forcing a patient to go back to their GP”.
“We are looking at a perfect storm of medicine supply challenges coupled with soaring prices with pharmacy owners all too often footing the bill of our medicines,” Picard added.
Responding to the NPA’s analysis, Community Pharmacy England’s director of research and insights James Davies said: “The medicines supply situation remains troubling, as pharmacy owners and their teams know only too well.
“They regularly go above and beyond to get hold of medicines for their patients, often at a personal cost and despite a host of other financial and operational pressures they face.
“Patients and pharmacies deserve better. They urgently need lasting action from Government to address some of the economic root causes of these shortages and build greater resilience into the medicines supply chain.”